Novel therapeutics for metastatic renal cell carcinoma

Authors

  • Thomas E. Hutson DO, PharmD,

    1. Genitourinary Oncology Program, Baylor Sammons Cancer Center, Dallas, Texas
    Search for more papers by this author
  • Robert A. Figlin MD

    Corresponding author
    1. Division of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California
    • Division of Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010
    Search for more papers by this author
    • Fax: (626) 301-8233;


  • This educational proceedings publication is based on a symposium held on June 27-28, 2008, in Cambridge, Massachusetts.

Abstract

The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically during the past few years. Sunitinib malate, sorafenib tosylate, bevacizumab with interferon α, temsirolimus, and everolimus have improved clinical outcomes in randomized phase 3 trials by inhibiting the vascular endothelial growth factor and related pathways. Combinations and sequences of these agents are being evaluated. Other novel agents are in clinical development, some of which target novel pathways not yet exploited as therapy for RCC. Recently reported and ongoing clinical trials will help further define the role of these agents as therapy for metastatic RCC. Cancer 2009;115(10 suppl):2361-7. © 2009 American Cancer Society.

Ancillary